X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Dr. Reddy: 2Q PAT down 31% - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Oct 24, 2002

    Dr. Reddy: 2Q PAT down 31%

    Dr. Reddy's, after reporting solid growth over the past year, has registered a decline in turnover. The drop in sales is primarily due to slowdown in fluoxetine sales, which has reflected across the income statement. The company has continued to show good growth in active pharma ingredients (API) business and branded formulations.

    (Rs m) 2QFY02 2QFY03 Change 1HFY02 1HFY03 Change
    Net Sales 4,739 4,037 -14.8% 7,375 7,387 0.2%
    Other Income 204 167 -17.9% 290 334 15.2%
    Expenditure 2,298 2,934 27.7% 4,280 5,346 24.9%
    Operating Profit (EBDIT) 2,442 1,103 -54.8% 3,096 2,042 -34.1%
    Operating Profit Margin (%) 51.5% 27.3%   42.0% 27.6%  
    Interest 14 13 -8.4% 64 27 -58.1%
    Depreciation 122 144 18.6% 234 281 20.0%
    Profit before Tax 2,510 1,114 -55.6% 3,087 2,068 -33.0%
    Extraordinary income (1,083) -   (1,083) -  
    Tax (8) 122 -1677.9% 35 274 694.5%
    Profit after Tax/(Loss) 1,434 992 -30.8% 1,969 1,793 -8.9%
    Net profit margin (%) 30.3% 24.6%   26.7% 24.3%  
    No. of Shares (eoy) (m) 38.3 76.5   38.3 76.5  
    Fully Diluted Earnings per share* 75.0 51.9   51.5 46.9  
    P/E Ratio         15.5  

    In our earlier reports, we had indicated that sales from fluoxetine business are expected to decline. Adjusting for the same, sales in the half-year period have increased by 22% YoY. The API business is likely to have continued to performed well on the back of Tizanidine and Doxazosin. API exports are expected to catapult in the future considering the fact that the company has filed 3 DMF's (Drug Master Filings) in 4QFY02 and is likely to have made more filings last quarter.

    In branded formulations, the company reported a overall 14% growth including both domestic and international business. The growth in the domestic market could have been facilitated by dental products. It may be recalled that the company acquired 6 dental brands in India from a local Indian company (Groupe Pharma) last year, which has added to domestic formulations sales in the current year.

    As mentioned earlier, financials are reflecting the effect of decline in fluoxetine sales. Marketing exclusivity for fluoxetine expired in January '02 leading to sharp price erosion (almost 80%), as two other competitors have entered the market. That said, with revenues from new businesses supporting organisational expansion and increased R&D expense, a similar buffer has not been present in quarter ended September '02 leading to drop in margins. R&D expense for the quarter has almost doubled from 4.5% to 8.6% of net sales.

    At Rs 726, the scrip is trading on a multiple of 15.5x 1HFY03 annualised stand-alone earnings, as compared to 20.2x 1QFY03 annualised stand-alone earnings. It may be recalled that the company received a major setback in 2Q with suspension of clinical trials for the outlicensed anti-diabetic molecule (Ragaglitazar). Also, there were concerns that the company delayed disclosing the Ragaglitazar setback. We had mentioned that moving towards a research oriented business model could lead to lumpiness in earnings before a steady drug pipeline is built.

     

     

    Equitymaster requests your view! Post a comment on "Dr. Reddy: 2Q PAT down 31%". Click here!

      
     

    More Views on News

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

    Sep 12, 2016

    Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

    Aug 4, 2017

    The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    DR. REDDYS LAB SHARE PRICE


    Aug 16, 2017 (Close)

    TRACK DR. REDDYS LAB

    • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    DR. REDDYS LAB - ADCOCK INGRAM COMPARISON

    Compare Company With Charts

    COMPARE DR. REDDYS LAB WITH

    MARKET STATS